Objective: To investigate the treatment effect of TURP plus urethral sphincter botox A injection on male neurogenic micturition dysfunction. Methods: Sixteen cases of male neurogenic bladder dysfunction patients. Age from 50 to 68 years old. Average 56 years old. All patients have dysuria symptom with normal bladder capacity. Detrusor underactivity 15 cases. Normal detrusor contractility 1 case. Reasons for neurogenic bladder: spinal cord injury 8 cases, spinal cord tumor 3 cases, postencephalitic 1 case, unknown reasons 4 cases, re-injection 1 case. Residual urine from 80 to 220 mL. Different degrees of prostatic hyperplasia were verified by ultrasound in 15 cases. Routine TURP were administrated under plasma cystoscopy. 100u botox A was injected into urethral sphincter muscle in 10 spots evenly. Symptom scores and ultrasound residual urine were recorded before and 4 weeks after surgery. Results were analyzed for treatment effect estimation. Results: The average residual urine volume reduced from 154.8sidua to 57.3erage mL (P<0.01). Three cases stress urinary incontinence were observed, and reduced or recovered after 2-3 months pelvic floor muscle training. All patients were satisfied with the treatment results. The treatment effect lasted more than 15 months. Conclusions: TURP plus urethral sphincter botox A injection is an effective and economic treatment on male neurogenic micturition dysfunction. Objective: To assess the clinical efficacy and safety of administering doxazosin as an alpha 1-blocker in patients with comorbid LUTS/BPH and mild hypertension. Methods: One hundred and fifty-six enrolled men concomitant with comorbid LUTS/BPH and mild hypertension who completed the International Prostate Symptom Score (IPSS >7 points) at the first visit in our clinic were eligible in this trial. All the patients were assessed based on IPSS, IPSS-Quality of Life for LUTS/ BPH and received blood pressure (BP) determination. Those men with normotensive and moderate-to-severe hypertension were excluded. Urologic and cardiologic assessment included uroflowmetry (maximum urinary flow rate, Qmax), IPSS, and BP measurements. They were administered with 4 mg of doxazosin once daily for 12 weeks. Changes of IPSS, Qmax, Quality of Life for LUTS/BPH, systolic and diastolic BP were evaluated every 4 weeks. Safety was mainly assessed via spontaneous reports of adverse events. Results: After treatment with doxazosin, IPSS in those LUTS/BPH men significantly decreased (15.2±4.8 vs. 10.7±3.5 points, P<0.001), whereas Qmax increased (9.4±2.5 and 11.8±4.3 mL/s, P<0.01), respectively. Doxazosin demonstrated efficacy in lowering IPSS score and relieving LUTS. Of them, systolic and diastolic BP of 124 patients (79.5%) decreased to normal. Most patients were generally well tolerant to the treatment and there was no evidence
Objective: To assess the clinical efficacy and safety of administering doxazosin as an alpha 1-blocker in patients with comorbid LUTS/BPH and mild hypertension. Methods: One hundred and fifty-six enrolled men concomitant with comorbid LUTS/BPH and mild hypertension who completed the International Prostate Symptom Score (IPSS >7 points) at the first visit in our clinic were eligible in this trial. All the patients were assessed based on IPSS, IPSS-Quality of Life for LUTS/ BPH and received blood pressure (BP) determination. Those men with normotensive and moderate-to-severe hypertension were excluded. Urologic and cardiologic assessment included uroflowmetry (maximum urinary flow rate, Qmax), IPSS, and BP measurements. They were administered with 4 mg of doxazosin once daily for 12 weeks. Changes of IPSS, Qmax, Quality of Life for LUTS/BPH, systolic and diastolic BP were evaluated every 4 weeks. Safety was mainly assessed via spontaneous reports of adverse events. Results: After treatment with doxazosin, IPSS in those LUTS/BPH men significantly decreased (15.2±4.8 vs. 10.7±3.5 points, P<0.001), whereas Qmax increased (9.4±2.5 and 11.8±4.3 mL/s, P<0.01), respectively. Doxazosin demonstrated efficacy in lowering IPSS score and relieving LUTS. Of them, systolic and diastolic BP of 124 patients (79.5%) decreased to normal. Most patients were generally well tolerant to the treatment and there was no evidence of additional side effects related to administration. No orthostatic hypotension and other BP-related adverse profiles occurred in all patients. Conclusions: Our data show that doxazosin as an alpha 1-blocker treatment appears to be efficacious in both relieving bothersome lower urinary tract symptoms and decreasing BP in LUTS/BPH men with mild hypertension. Objective: Transumbilical single incision surgery (TSIS) has recently gained popularity for symptomatic renal cysts. We evaluated the clinical utility and safety of homemade glove port device in bilateral renal cyst decortication patients at our institution. Methods: We reviewed our series of 42 bilateral symptomatic renal cyst (range, 4-12 cm) decortication performed from November 2010 to December 2013. A homemade port device consisted of two control loops and a glove to form three channels was placed through the umbilical single incision. A homemade single port device was made by fixing a size 7 1/2 surgical glove to the retractor outer ring and securing the glove fingers to the end of three trocars with a tie. The homemade port was inserted at the umbilical incision, operation was performed by using a special flexible 30-degree laparoscope and conventional laparoscopic instruments. Results: All cases were completed successfully, without conversion to a standard laparoscopic or open approach. The average operative time was 75 min and the estimated blood loss was less than 30 mL, no intraoperative complication occurred. The mean hospital stay was 2.8 d lap [2] [3] [4] [5] days, with a median follow-up of 20 months (range, 8-32) there was no recurrence. Conclusions: Our homemade single port device is costeffective and more flexible to deal with bilateral renal cysts especially ventral lesions than the current multichannel port or traditional laparoscopic surgery. 
